• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Centessa Pharmaceuticals plc

    5/27/25 4:02:14 PM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CNTA alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001400975
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Centessa Pharmaceuticals plc
    SEC File Number
    001-40445
    Address of Issuer
    3RD FLOOR
    1 ASHLEY ROAD
    ALTRINCHAM, CHESHIRE
    UNITED KINGDOM
    WA14 2DT
    Phone
    44 7391 789784
    Name of Person for Whose Account the Securities are To Be Sold
    Weinhoff Gregory M
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    UBS Financial Services Inc.
    11 Madison Ave
    4th Floor
    New York � NY � 10010
    10000128225.0013361877405/27/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common05/27/2025Exercise of Stock OptionsIssuerCheckbox not checked1000005/27/2025Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Gregory Weinhoff
    3rd Floor
    1 Ashley Road
    Altrincham, Cheshire � X0 � WA142DT
    Common03/25/202510000163386.00
    Gregory Weinhofff
    3rd Floor, 1 Ashley Road
    Altrincham � X0 � X0 WA142DT
    Common04/25/202511742159856.76

    144: Remarks and Signature

    Remarks
    The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan.
    Date of Notice
    05/27/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    05/22/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ UBS Financial Services Inc, as attorney-in-fact for Gregory Weinhoff

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $CNTA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CNTA

    DatePrice TargetRatingAnalyst
    5/28/2025$35.00Buy
    Needham
    5/8/2025$30.00Buy
    Chardan Capital Markets
    3/31/2025$38.00Overweight
    Piper Sandler
    1/7/2025Buy
    TD Cowen
    9/20/2024$11.00 → $26.00Equal-Weight → Overweight
    Morgan Stanley
    9/19/2024$33.00Buy
    B. Riley Securities
    7/18/2024$14.00Outperform
    Oppenheimer
    11/15/2023$4.00 → $11.00Hold → Buy
    Jefferies
    More analyst ratings

    $CNTA
    Financials

    Live finance-specific insights

    See more
    • Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025

      Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) on track with data expected across all three indications this year with first-in-class potential in NT2 and IHORX142 on track to initiate first-in-human studies for the treatment of neurological and neurodegenerative disorders with clinical data in acutely sleep-deprived healthy volunteers planned for this yearORX489 advancing in IND-enabling studies for the treatment of neuropsychiatric disorders BOSTON and LONDON, May 14, 20

      5/14/25 7:00:53 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023

      SerpinPC: Ongoing registrational PRESent-2 and PRESent-3 studies for the treatment of hemophilia B; New data from ongoing Phase 2a study accepted for poster presentation at American Society of Hematology (ASH) Annual Meeting in December 2023 ORX750: Preclinical data supporting potential best-in-class profile for the treatment of narcolepsy and other sleep-wake disorders presented at World Sleep Congress; Advancing in IND-enabling studies; Clinical proof of concept data planned for 2024LockBody® Technology Platform: Ongoing Phase 1/2a study of LB101 (PD-L1xCD47) for the treatment of solid tumors BOSTON and LONDON, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA

      11/13/23 4:05:10 PM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023

      Enrollment and dosing ongoing in registrational study of SerpinPC for the treatment of hemophilia BEnrollment and dosing ongoing in Phase 1/2a Study of LB101, a PD-L1xCD47 LockBody® for the treatment of solid tumors IND-enabling activities advancing for ORX750, an oral selective orexin receptor 2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; Announces ORX750 preclinical data to be presented at World Sleep Congress in October 2023 Nominates second LockBody candidate, LB206, a conditionally bivalent PD-L1xCD3 bispecific monoclonal antibody BOSTON and LONDON, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceuti

      8/14/23 7:00:30 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $CNTA
    Leadership Updates

    Live Leadership Updates

    See more

    $CNTA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Needham initiated coverage on Centessa Pharmaceuticals with a new price target

      Needham initiated coverage of Centessa Pharmaceuticals with a rating of Buy and set a new price target of $35.00

      5/28/25 9:07:36 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chardan Capital Markets initiated coverage on Centessa Pharmaceuticals with a new price target

      Chardan Capital Markets initiated coverage of Centessa Pharmaceuticals with a rating of Buy and set a new price target of $30.00

      5/8/25 8:28:10 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Centessa Pharmaceuticals with a new price target

      Piper Sandler initiated coverage of Centessa Pharmaceuticals with a rating of Overweight and set a new price target of $38.00

      3/31/25 8:13:04 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer

      BOSTON and LONDON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients, today announced the appointment of Stephen Kanes MD PhD, as Chief Medical Officer (CMO). Dr. Kanes is a neuropsychiatrist, with a career in neuroscience, clinical psychiatry, and neuroscience drug development spanning more than 30 years.  "Centessa is rapidly advancing a potential best-in-class and first-in-class portfolio of orexin receptor 2 (OX2R) agonists with a robust series of clinical milestones anticipated this year," said Saurabh Saha MD

      1/8/25 7:05:00 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer

      BOSTON and LONDON, June 10, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that John Crowley CPA, has been appointed Chief Financial Officer, and Gregory Weinhoff MD MBA, former Chief Financial Officer, has been appointed to the newly created role of Chief Business Officer, effective June 10, 2024. "With all three of our core programs in the clinic, we believe we have solidified a strong foundation and are poised for our next exciting chapter as a company. To best position Centessa for this pivotal time, we've added key new talen

      6/10/24 7:00:00 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Centessa Pharmaceuticals Announces Additions to Senior Leadership Team

      BOSTON and LONDON, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the appointment of April Dovholuk and Ellie Im, MD to Centessa's executive team as Senior Vice President of Development Operations and Senior Vice President of Clinical Development, Oncology, respectively. In these newly created roles, Ms. Dovholuk will lead both Centessa's global Clinical Trials and Development Operations teams, and Dr. Im will manage clinical development of the Company's Oncology programs based on the LockBody® technology platform. "We a

      10/3/23 8:00:00 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

      BOSTON and LONDON, May 19, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences: Event: Jefferies 2025 Global Healthcare Conference Date: June 4, 2025Fireside Chat: 11:40 AM ET Event: Goldman Sachs 46th Annual Global Healthcare ConferenceDate: June 10, 2025Fireside Chat: 9:20 AM ET Access to the live webcasts of these events, as well as archived recordings, will be available under the "Events and Publications" tab on the investor

      5/19/25 8:00:00 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025

      Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) on track with data expected across all three indications this year with first-in-class potential in NT2 and IHORX142 on track to initiate first-in-human studies for the treatment of neurological and neurodegenerative disorders with clinical data in acutely sleep-deprived healthy volunteers planned for this yearORX489 advancing in IND-enabling studies for the treatment of neuropsychiatric disorders BOSTON and LONDON, May 14, 20

      5/14/25 7:00:53 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024

      Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise with key data readouts expected in 2025 ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) well underway and on track with data expected across all three indications in 2025 with first-in-class potential in NT2 and IHORX142 in IND-enabling studies for the treatment of neurological and neurodegenerative disorders; Clinical data in acutely sleep-deprived healthy volunteers planned for 2025ORX489 in IND-enabling studies for the treatment of neuropsychiatric disorders BOSTON and LONDON, March 24, 2025 (GLOBE NEWSWIRE) -- Cent

      3/24/25 7:00:49 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Business Officer Weinhoff Gregory M exercised 10,000 units of Ordinary Shares at a strike of $3.85 and sold $128,225 worth of Ordinary Shares (10,000 units at $12.82) (SEC Form 4)

      4 - Centessa Pharmaceuticals plc (0001847903) (Issuer)

      5/27/25 6:31:36 PM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Saha Saurabh exercised 55,000 units of Ordinary Shares at a strike of $3.85 and sold $699,110 worth of Ordinary Shares (55,000 units at $12.71) (SEC Form 4)

      4 - Centessa Pharmaceuticals plc (0001847903) (Issuer)

      5/20/25 5:44:05 PM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Goyal Arjun bought $5,865,242 worth of Ordinary Shares (462,585 units at $12.68) (SEC Form 4)

      4 - Centessa Pharmaceuticals plc (0001847903) (Issuer)

      5/19/25 5:49:01 PM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Centessa Pharmaceuticals plc

      SC 13G/A - Centessa Pharmaceuticals plc (0001847903) (Subject)

      11/14/24 5:43:48 PM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Centessa Pharmaceuticals plc

      SC 13G/A - Centessa Pharmaceuticals plc (0001847903) (Subject)

      11/14/24 4:20:32 PM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Centessa Pharmaceuticals plc (Amendment)

      SC 13G/A - Centessa Pharmaceuticals plc (0001847903) (Subject)

      2/14/24 5:37:34 PM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNTA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Goyal Arjun bought $5,865,242 worth of Ordinary Shares (462,585 units at $12.68) (SEC Form 4)

      4 - Centessa Pharmaceuticals plc (0001847903) (Issuer)

      5/19/25 5:49:01 PM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNTA
    SEC Filings

    See more
    • Centessa Pharmaceuticals plc filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Centessa Pharmaceuticals plc (0001847903) (Filer)

      5/29/25 8:08:42 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Centessa Pharmaceuticals plc

      DEFA14A - Centessa Pharmaceuticals plc (0001847903) (Filer)

      5/28/25 9:15:45 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Centessa Pharmaceuticals plc

      144 - Centessa Pharmaceuticals plc (0001847903) (Subject)

      5/27/25 4:02:14 PM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care